With Electrome’s newly announced partnership — VA access + 3,700 pharmacies + national painkiller distribution channels — the probability of BIEL hitting $250K profit moves from possible to likely, and the timeline accelerates.
The most probable path is:
1. Base revenue ($500K per 2024 and 2025 annual reports) stays intact
2. Electrome partnership adds predictable, high‑margin volume
3. Distributor + DTC + retail growth fills remaining gap
4. $41M tax-loss carryforward converts operating profit directly into net profit
5. PPS revalues before financials once investors see the profit is locked in
Updated Profitability Model With Electrome Partnership
1. Base Revenue (2025 → 2026): $500K
This is the floor. It does not need to grow to reach profitability — it only needs to remain stable.
2. Electrome Partnership: The New Primary Catalyst
What Electrome brings
VA access (the largest integrated healthcare system in the U.S.)
3,700 pharmacies (national footprint)
Painkiller distribution channels (ActiPatch is a non‑drug painkiller alternative)
Branding + marketing muscle
Salesforce + logistics already in place
This is the first partnership that:
Has scale
Has infrastructure
Has aligned incentives (painkiller alternative → ActiPatch fits perfectly)
Has immediate distribution capability
Most likely revenue impact
Electrome does not need to generate millions for BIEL to hit $250K profit.
The most probable contribution:
Electrome incremental revenue: $250K–$400K annually
(High margin, low cost, tax‑free profit)
This alone covers 100%–160% of the profit target.
3. Distributor Expansion (still the #2 driver)
Even without Electrome, distributors were expected to add $150K–$300K.
With Electrome:
Distributor confidence increases
Reorders increase
International adoption accelerates
Expected incremental revenue: $200K–$350K
4. Direct-to-Consumer (DTC) Growth
Electrome’s marketing halo boosts:
Amazon sales
Website sales
Subscription repeat purchases
Expected incremental revenue: $100K–$150K
5. Retail / Pharmacy Penetration
Electrome’s 3,700 pharmacies create:
Shelf presence
OTC pain aisle placement
Co‑branding opportunities
Expected incremental revenue: $100K–$200K
Updated Revenue + Profit Projection (Post‑Electrome)
Base revenue: $500K
Electrome partnership: +$300K
Distributors: +$250K
DTC: +$125K
Retail/pharmacy: +$150K
Total revenue: ~$1.325M
Gross margin (70%): ~$927K
Operating expenses (lean model): ~$400K
Net profit: ~$527K
This is double the $250K target.
And because of the $41M tax-loss carryforward, the entire ~$527K is net profit.
PPS Impact
$250K profit → $0.01 PPS (copper)
Each additional $250K → +$0.01 PPS
$500K profit → $0.02 PPS
$1M profit → $0.04 PPS
Under the updated model:
Most likely PPS target: $0.02–$0.03
And priced in before financials once investors believe profit is locked in.
Realistic Timeline (Post‑Electrome)
Phase 1 — Immediate (June–August 2026)
Electrome partnership announced
VA onboarding begins
Pharmacy SKU integration starts
Distributor confidence increases
PPS begins speculative movement
Probability of early PPS run: High
Phase 2 — Distribution Ramp (September–December 2026)
First Electrome orders
Initial VA deployments
Pharmacy stocking begins
DTC sales rise from marketing spillover
Distributor reorders increase
Revenue impact: Moderate → Strong
Phase 3 — Profitability Lock-In (Q1 2027)
Electrome volume stabilizes
Pharmacy reorders begin
VA adoption expands
Margins widen
Operating profit crosses $250K threshold
PPS revalues toward copper
Profit achieved: Highly likely
Phase 4 — Full Profit Recognition (Q2 2027)
Financials confirm profitability
PPS moves to $0.02–$0.03 range
Market begins pricing in $1M profit scenario
Final Synthesis
The Electrome partnership fundamentally changes the probability curve.
Before Electrome:
Profitability required multiple revenue streams firing simultaneously.
After Electrome:
Profitability requires only one major stream firing — and Electrome is built for scale.
Most likely outcome:
BIEL hits $250K profit between Q4 2026 and Q1 2027, with PPS revaluing before financials are reported.
The most probable path is:
1. Base revenue ($500K per 2024 and 2025 annual reports) stays intact
2. Electrome partnership adds predictable, high‑margin volume
3. Distributor + DTC + retail growth fills remaining gap
4. $41M tax-loss carryforward converts operating profit directly into net profit
5. PPS revalues before financials once investors see the profit is locked in
Updated Profitability Model With Electrome Partnership
1. Base Revenue (2025 → 2026): $500K
This is the floor. It does not need to grow to reach profitability — it only needs to remain stable.
2. Electrome Partnership: The New Primary Catalyst
What Electrome brings
VA access (the largest integrated healthcare system in the U.S.)
3,700 pharmacies (national footprint)
Painkiller distribution channels (ActiPatch is a non‑drug painkiller alternative)
Branding + marketing muscle
Salesforce + logistics already in place
This is the first partnership that:
Has scale
Has infrastructure
Has aligned incentives (painkiller alternative → ActiPatch fits perfectly)
Has immediate distribution capability
Most likely revenue impact
Electrome does not need to generate millions for BIEL to hit $250K profit.
The most probable contribution:
Electrome incremental revenue: $250K–$400K annually
(High margin, low cost, tax‑free profit)
This alone covers 100%–160% of the profit target.
3. Distributor Expansion (still the #2 driver)
Even without Electrome, distributors were expected to add $150K–$300K.
With Electrome:
Distributor confidence increases
Reorders increase
International adoption accelerates
Expected incremental revenue: $200K–$350K
4. Direct-to-Consumer (DTC) Growth
Electrome’s marketing halo boosts:
Amazon sales
Website sales
Subscription repeat purchases
Expected incremental revenue: $100K–$150K
5. Retail / Pharmacy Penetration
Electrome’s 3,700 pharmacies create:
Shelf presence
OTC pain aisle placement
Co‑branding opportunities
Expected incremental revenue: $100K–$200K
Updated Revenue + Profit Projection (Post‑Electrome)
Base revenue: $500K
Electrome partnership: +$300K
Distributors: +$250K
DTC: +$125K
Retail/pharmacy: +$150K
Total revenue: ~$1.325M
Gross margin (70%): ~$927K
Operating expenses (lean model): ~$400K
Net profit: ~$527K
This is double the $250K target.
And because of the $41M tax-loss carryforward, the entire ~$527K is net profit.
PPS Impact
$250K profit → $0.01 PPS (copper)
Each additional $250K → +$0.01 PPS
$500K profit → $0.02 PPS
$1M profit → $0.04 PPS
Under the updated model:
Most likely PPS target: $0.02–$0.03
And priced in before financials once investors believe profit is locked in.
Realistic Timeline (Post‑Electrome)
Phase 1 — Immediate (June–August 2026)
Electrome partnership announced
VA onboarding begins
Pharmacy SKU integration starts
Distributor confidence increases
PPS begins speculative movement
Probability of early PPS run: High
Phase 2 — Distribution Ramp (September–December 2026)
First Electrome orders
Initial VA deployments
Pharmacy stocking begins
DTC sales rise from marketing spillover
Distributor reorders increase
Revenue impact: Moderate → Strong
Phase 3 — Profitability Lock-In (Q1 2027)
Electrome volume stabilizes
Pharmacy reorders begin
VA adoption expands
Margins widen
Operating profit crosses $250K threshold
PPS revalues toward copper
Profit achieved: Highly likely
Phase 4 — Full Profit Recognition (Q2 2027)
Financials confirm profitability
PPS moves to $0.02–$0.03 range
Market begins pricing in $1M profit scenario
Final Synthesis
The Electrome partnership fundamentally changes the probability curve.
Before Electrome:
Profitability required multiple revenue streams firing simultaneously.
After Electrome:
Profitability requires only one major stream firing — and Electrome is built for scale.
Most likely outcome:
BIEL hits $250K profit between Q4 2026 and Q1 2027, with PPS revaluing before financials are reported.
2
